Tuesday, 21 Jan 2020

You are here

Febuxostat Safe in Gout with Moderate-Severe Renal Impairment

Renal impairment is a risk factor for gout and a barrier to optimal gout management. Many of the drugs used to treat gout require adjustment in those with renal disease.

The product label for febuxostat states that "no dose adjustment is necessary in patients with mild or moderate renal impairment (Clcr 30 to 89 mL/min) and that there are insufficient data on patients with severe renal impairment (Clcr less than 30 mL/min). Hence, caution is advised for such patients.

Renal adverse events reported with febuxostat include hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, urgency, incontinence, an tubulointerstitial nephritis.

The safety and efficacy of febuxostat in patients with moderate to severe renal impairment (GFR ≥ 15 to < 50 mL/min) are limited. Saag and colleagues have studied 96 subjects with moderate to severe renal impairment and gout over a 12 month period in a randomized, double-blind, placebo-controlled study using febuxostat 30 mg BID, febuxostat 40/80 mg QD, or placebo.

After 12 month, the change from baseline in serum creatinine was the same in either febuxostat group compared to placebo. However the number with with sUA < 6.0 mg/dL was significantly greater in both febuxostat groups compared to placebo.

Thus, febuxostat is effective and well tolerated in gout subjects with moderate to severe renal impairment. While monitoring is still advised, no initial dose adjustments are necessary. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.